Proceedings of the first global workshop on breast cancer

Pathways to the evaluation and clinical development of novel agents for breast cancer

Kathy S. Albain, Lisa Carey, William J. Gradishar, Julie R. Gralow, Allan Lipton, Hope Rugo, Debu Tripathy, Susan Peck, Tristin Abair, Mark Pegram

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The number of treatment options available to patients with breast cancer is larger and more complex than ever before. This is due in part to increased understanding of breast cancer tumor biology and the signaling pathways involved in tumor development and progression, which drives new areas of breast cancer research and the development of novel agents. Therapies targeting HER2 signaling, angiogenesis, DNA repair, and many other essential cellular processes that are dysregulated in cancer have produced significant improvements in disease outcome, although careful patient selection and toxicity management are required to maximize their therapeutic potential. Multigene assays have added to the ability to predict disease outcome and degree of response to adjuvant chemotherapy, but the application of these assays in the right clinical context is necessary. Unfortunately, despite the use of appropriate and effective local and adjuvant therapies, some patients with early-stage breast cancer will eventually develop metastatic disease. Most of these patients will have received standard therapies in the adjuvant setting and/or will develop resistance to these therapies at some point during treatment. Thus, implementation of novel strategies is necessary to overcome resistance and improve disease outcome. This in turn will require creative clinical trial designs, more efficient accrual, and rapid translation of results into the clinical setting. This summary highlights selected challenges in the current management of breast cancer and discusses expert perspectives, key questions, areas of debate, and future directions.

Original languageEnglish (US)
Pages (from-to)421-439
Number of pages19
JournalClinical Breast Cancer
Volume10
Issue number6
DOIs
StatePublished - Jan 1 2010

Fingerprint

Breast Neoplasms
Education
Therapeutics
Disease Resistance
Adjuvant Chemotherapy
DNA Repair
Patient Selection
Neoplasms
Clinical Trials
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Albain, Kathy S. ; Carey, Lisa ; Gradishar, William J. ; Gralow, Julie R. ; Lipton, Allan ; Rugo, Hope ; Tripathy, Debu ; Peck, Susan ; Abair, Tristin ; Pegram, Mark. / Proceedings of the first global workshop on breast cancer : Pathways to the evaluation and clinical development of novel agents for breast cancer. In: Clinical Breast Cancer. 2010 ; Vol. 10, No. 6. pp. 421-439.
@article{020d855d582543e2b18b501dc971e30f,
title = "Proceedings of the first global workshop on breast cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer",
abstract = "The number of treatment options available to patients with breast cancer is larger and more complex than ever before. This is due in part to increased understanding of breast cancer tumor biology and the signaling pathways involved in tumor development and progression, which drives new areas of breast cancer research and the development of novel agents. Therapies targeting HER2 signaling, angiogenesis, DNA repair, and many other essential cellular processes that are dysregulated in cancer have produced significant improvements in disease outcome, although careful patient selection and toxicity management are required to maximize their therapeutic potential. Multigene assays have added to the ability to predict disease outcome and degree of response to adjuvant chemotherapy, but the application of these assays in the right clinical context is necessary. Unfortunately, despite the use of appropriate and effective local and adjuvant therapies, some patients with early-stage breast cancer will eventually develop metastatic disease. Most of these patients will have received standard therapies in the adjuvant setting and/or will develop resistance to these therapies at some point during treatment. Thus, implementation of novel strategies is necessary to overcome resistance and improve disease outcome. This in turn will require creative clinical trial designs, more efficient accrual, and rapid translation of results into the clinical setting. This summary highlights selected challenges in the current management of breast cancer and discusses expert perspectives, key questions, areas of debate, and future directions.",
author = "Albain, {Kathy S.} and Lisa Carey and Gradishar, {William J.} and Gralow, {Julie R.} and Allan Lipton and Hope Rugo and Debu Tripathy and Susan Peck and Tristin Abair and Mark Pegram",
year = "2010",
month = "1",
day = "1",
doi = "10.3816/CBC.2010.n.056",
language = "English (US)",
volume = "10",
pages = "421--439",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

Proceedings of the first global workshop on breast cancer : Pathways to the evaluation and clinical development of novel agents for breast cancer. / Albain, Kathy S.; Carey, Lisa; Gradishar, William J.; Gralow, Julie R.; Lipton, Allan; Rugo, Hope; Tripathy, Debu; Peck, Susan; Abair, Tristin; Pegram, Mark.

In: Clinical Breast Cancer, Vol. 10, No. 6, 01.01.2010, p. 421-439.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proceedings of the first global workshop on breast cancer

T2 - Pathways to the evaluation and clinical development of novel agents for breast cancer

AU - Albain, Kathy S.

AU - Carey, Lisa

AU - Gradishar, William J.

AU - Gralow, Julie R.

AU - Lipton, Allan

AU - Rugo, Hope

AU - Tripathy, Debu

AU - Peck, Susan

AU - Abair, Tristin

AU - Pegram, Mark

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The number of treatment options available to patients with breast cancer is larger and more complex than ever before. This is due in part to increased understanding of breast cancer tumor biology and the signaling pathways involved in tumor development and progression, which drives new areas of breast cancer research and the development of novel agents. Therapies targeting HER2 signaling, angiogenesis, DNA repair, and many other essential cellular processes that are dysregulated in cancer have produced significant improvements in disease outcome, although careful patient selection and toxicity management are required to maximize their therapeutic potential. Multigene assays have added to the ability to predict disease outcome and degree of response to adjuvant chemotherapy, but the application of these assays in the right clinical context is necessary. Unfortunately, despite the use of appropriate and effective local and adjuvant therapies, some patients with early-stage breast cancer will eventually develop metastatic disease. Most of these patients will have received standard therapies in the adjuvant setting and/or will develop resistance to these therapies at some point during treatment. Thus, implementation of novel strategies is necessary to overcome resistance and improve disease outcome. This in turn will require creative clinical trial designs, more efficient accrual, and rapid translation of results into the clinical setting. This summary highlights selected challenges in the current management of breast cancer and discusses expert perspectives, key questions, areas of debate, and future directions.

AB - The number of treatment options available to patients with breast cancer is larger and more complex than ever before. This is due in part to increased understanding of breast cancer tumor biology and the signaling pathways involved in tumor development and progression, which drives new areas of breast cancer research and the development of novel agents. Therapies targeting HER2 signaling, angiogenesis, DNA repair, and many other essential cellular processes that are dysregulated in cancer have produced significant improvements in disease outcome, although careful patient selection and toxicity management are required to maximize their therapeutic potential. Multigene assays have added to the ability to predict disease outcome and degree of response to adjuvant chemotherapy, but the application of these assays in the right clinical context is necessary. Unfortunately, despite the use of appropriate and effective local and adjuvant therapies, some patients with early-stage breast cancer will eventually develop metastatic disease. Most of these patients will have received standard therapies in the adjuvant setting and/or will develop resistance to these therapies at some point during treatment. Thus, implementation of novel strategies is necessary to overcome resistance and improve disease outcome. This in turn will require creative clinical trial designs, more efficient accrual, and rapid translation of results into the clinical setting. This summary highlights selected challenges in the current management of breast cancer and discusses expert perspectives, key questions, areas of debate, and future directions.

UR - http://www.scopus.com/inward/record.url?scp=79952277808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952277808&partnerID=8YFLogxK

U2 - 10.3816/CBC.2010.n.056

DO - 10.3816/CBC.2010.n.056

M3 - Article

VL - 10

SP - 421

EP - 439

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -